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Purpose: This retrospective study was done to investigate the mean platelet vol-
ume (MPV) level in patients with psoriasis vulgaris and its relationship with dis-
ease severity. Materials and Methods: We undertook a cross-sectional study on 
176 patients and 101 healthy controls to examine the association between MPV 
and psoriasis. Various clinical and laboratory parameters were analyzed and com-
pared. Results: Platelet distribution width and MPV were significantly higher in 
patients with psoriasis than controls. In addition, there was positive correlation be-
tween Psoriasis Area Severity Index (PASI) and MPV. When psoriasis patients 
were grouped into mild psoriasis (PASI<10) and moderate to severe psoriasis 
(PASI≥10), the MPV of the latter group was significantly elevated. Nevertheless, 
patients with higher MPV level (MPV≥10.4 fL) did not show higher PASI than 
lower MPV level (MPV<10.4 fL). MPV levels significantly decreased after im-
provements of psoriasis with various treatments. The variations of MPV and PASI 
also showed significant correlation. Conclusion: We have shown that MPV is in-
creased in psoriasis patients and correlates with disease severity. Therefore, MPV 
levels may be considered as a marker of disease severity of psoriasis.
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INTRODUCTION
Platelets are known to play important roles in inflammatory reactions and immune 
responses.1 Platelets can be activated by various stimuli, and its activity is known 
to mediate immune-inflammatory process.2 The activity of platelets is assessed by 
measuring various platelet-derived secretory molecules, such as adhesion proteins, 
growth factors, chemokines, cytokines and coagulation factors.1 Besides, mean 
platelet volume (MPV) and platelet distribution width (PDW) have been exten-
sively studied and reported as platelet activation markers. Furthermore, MPV and 
PDW can be easily measured by automated hematology analyzer and these param-
eters are included in routine complete blood cell (CBC) analysis, and they are cost-
effective and easy way to measure platelet activation in daily routine practice. In 
fact, MPV levels are shown to be related to various diseases such as cardiovascu-
lar disease, peripheral artery disease, systemic lupus erythematosus, systemic scle-
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and ΔMPV [=MPV (before)-MPV (after)] were calculated. 
In this analysis, 6 additional patients, who showed disease 
aggravation during follow-ups, were included. 
Statistical analysis
Continuous parameters are described as means±SD and 
qualitative parameters as numbers and percentages. To de-
termine differences between psoriasis patients and healthy 
controls, Student’s t-test and Fisher’s exact test were used 
for continuous and qualitative parameters, respectively. The 
correlation between PASI and other parameters were evalu-
ated with Spearman’s rank correlation coefficient. In addi-
tion, psoriasis patients were grouped according to their PASI 
and MPV value and they were compared. Wilcoxon signed 
rank test was used for analysis of MPV levels before and af-
ter psoriasis treatments. The correlation between ΔPASI and 
ΔMPV was also evaluated with Spearman’s rank correla-
tion coefficient.
In all our analyses, differences were considered statisti-
cally significant when p value was less than 0.05. Statistical 
analyses were performed with SPSS version 17.0 (SPSS 
Inc., Chicago, IL, USA) or GraphPad Prism version 5.0 
(Graphpad, San Diego, CA, USA).
Exclusion criteria
The patients and healthy controls with following criteria were 
excluded from our study: other chronic inflammatory diseas-
es such as RA and inflammatory bowel diseases, hyperten-
sion, diabetes, cardiovascular disorders, cancers, overt infec-
tions, hematological diseases, chronic liver or kidney diseases, 
autoimmune disorders. 
RESULTS
 
One hundred and seventy-six psoriasis patients and 101 
healthy controls were included in our study. The demo-
graphic and laboratory characteristics are shown in Table 1. 
There were no significant differences in age, platelet count, 
BUN, and uric acid between the two groups, but there were 
significant differences in gender, Hb, WBC count, PDW, 
MPV, AST, ALT, Cr, and total cholesterol between the two 
groups. Though gender ratio between the two groups showed 
significant difference, there were no statistically differences 
in platelet count, PDW and MPV between male and female 
(data not shown). 
In psoriasis patients, we observed that PASI, most com-
rosis, rheumatoid arthritis (RA), osteoarthritis, vascular de-
mentia and Alzheimer’s disease and so on.3-6
Psoriasis is a common chronic recurrent inflammatory 
skin disease and platelet activation has been reported to be 
associated with its pathogenesis.2,7 Actually, there were two 
previous reports on MPV level in patients with psoriasis, but 
their results were different and one of the studies included 
only small study population.8,9 Therefore, in the present 
study, we aimed to stuey MPV levels in psoriasis patients 
and healthy controls in a larger study population.
MATERIALS AND METHODS
Study population
This is a retrospective study which included 176 patients 
with psoriasis. The participants were recruited between 1 
January 2012 and 31 December 2013 at our hospital. De-
mographic, clinical and laboratory information were re-
trieved from the database of our institute. Data were also 
collected from subjects who have taken medical checkups 
at our hospital for control group. 
All patients with psoriasis were fully evaluated by history 
taking and clinical examination. Psoriasis Area Severity In-
dex (PASI) was measured in all patients. Blood sampling 
was done at initial visit, and laboratory parameters were 
evaluated. They included hemoglobin (Hb), whole blood 
cell (WBC) count, platelet count, platelet distribution width 
(PDW), mean platelet volume (MPV), aspartate amino-
transferase (AST), alanine aminotransferase (ALT), blood 
urea nitrogen (BUN), creatinine (Cr), uric acid, cholesterol, 
erythrocyte sedimentation rate (ESR) and C-reactive pro-
tein (CRP). Unfortunately, routine blood testing for medical 
checkup did not include all the parameters described, com-
parison between the groups in some parameters were limit-
ed. Since CRP and ESR tests were not included in medical 
checkup at all, both parameters could not be compared be-
tween psoriasis patients and control subjects. Platelet count, 
PDW, MPV, Hb, and WBC count were included in routine 
CBC test and they were measured using an autoanalyzer 
(Sysmex XE-2100, Kobe, Japan). 
The MPV levels before and after psoriasis treatments 
were evaluated in 12 patients. Treatment modalities varied, 
including biologics, systemic medications, topical agents 
and narrow-band ultraviolet B. In addition, in order to find 
relationship between variations of PASI and MPV levels 
among 12 patients, ΔPASI [=PASI (after)-PASI (before)]
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count, PDW, AST, ALT, BUN, Cr, and cholesterol (Table 
2). In addition, PASI was not different between male and 
female (p=0.091). 
Next, we grouped patients into two groups according to 
their PASI score. PASI≥10 is generally regarded as moder-
monly used clinical assessment tool for disease severity, 
significantly correlated with MPV (r=0.189, p=0.006), ESR 
(r=0.165, p=0.023), CRP (r=0.152, p=0.03), and uric acid (r 
=0.187, p=0.007) (Fig. 1). However, PASI did not show 
significant correlation with age, Hb, WBC count, platelet 
Table 1. Clinical Charateristics of Psoriasis Patients and Healthy Controls
Characteristics Psoriasis patients (n=176) Healthy controls (n=101) p value
Age (yrs)   39.82±15.16   37.02±15.44   0.071
Gender (n, M/F) 114/62 42/59 <0.001
Hemoglobin (g/dL)   14.5±1.51 14.14±1.41   0.024
WBC count (103/uL)   6.82±1.86   6.09±1.52   0.001
Platelet count (103/uL)   248.0±47.69   249.9±41.23   0.368
PDW (fL) 11.48±1.45 10.98±1.16   0.002
MPV (fL)   9.92±0.73 9.724±0.59   0.009
AST (IU/L) 21.48±8.99 (n=173) 17.50±6.33 (n=74) <0.001
ALT (IU/L)   25.31±19.17 (n=173) 15.59±7.95 (n=73) <0.001
BUN (mg/dL) 13.34±3.96 (n=172)   13.0±3.46 (n=26)   0.339
Creatinine (mg/dL)   0.85±0.18 (n=172)   0.73±0.15 (n=77) <0.001
Uric acid (mg/dL)   5.27±1.35 (n=170) 4.85±1.1 (n=26)   0.066
Cholesterol (mg/dL)   185.3±36.82 (n=163)   199.5±36.87 (n=28) 0.03
ESR (mm/hr) 16.07±16.7 (n=147)
CRP (mg/L)   2.75±8.03 (n=153)
WBC, whole blood cell; PDW, platelet distribution width; MPV, mean platelet volume; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Fig. 1. The correlations between PASI and (A) MPV, (B) ESR, (C) uric acid, (D) CRP in patients with psoriasis are depicted. PASI, Psoriasis Area Severity 
Index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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ment (p=0.003) (Fig. 4A). Furthermore, the variation of 
PASI showed significant correlation with the variation of 
MPV in psoriasis patients (r=0.428, p=0.038) (Fig. 4B).
DISCUSSION
Until now, there have been many studies on biomarkers in 
psoriasis.10 However, there are yet no clinically useful bio-
ate to severe psoriasis and PASI<10 as mild psoriasis. The 
number of patients with PASI<10 was 124 and 52 patients 
had PASI≥10. Demographic and laboratory parameters 
were compared between two groups (Table 3). The mean 
MPV level of PASI≥10 patients was statistically higher 
than that of PASI<10 patients (p=0.038) (Fig. 2). Unexpect-
edly, BUN level was increased in mild psoriasis patients 
compared to moderate and severe patients (p=0.045). There 
were no significant differences in other parameter between 
two groups. 
Psoriasis patients were grouped according to their MPV 
value and PASI score was compared (Fig. 3). Subjects were 
grouped on the basis of MPV value 10.4 fL, since this is up-
per limit of reference range at our center. However, no differ-
ence of PASI was observed between two groups (p=0.2651). 
Other parameters were also compared between two groups, 
and platelet count, PDW and Hb level were found to have 
significant differences between two groups (Table 4). These 
differences do not seem to imply clinical significance, since 
PDW and platelet count are directly and inversely propor-
tional to MPV, respectively. Also, hemoglobin level in each 
group was in normal range. 
Lastly, we evaluated MPV levels of psoriatic patients be-
fore and after the treatment. They received various treat-
ments and showed at least modest improvements of PASI 
after the treatments. The mean MPV values before and after 
the treatment were 9.97 and 9.22, respectively. Wilcoxon 
signed rank test were performed and there was significant 
decrease of MPV level in each individual after the treat-
Table 2. Correlation of PASI with Various Parameters
Characteristics
Spearman rank 
correlation 
r value
p value
Age (yrs) 0.060 0.216
Hemoglobin (g/dL) 0.074 0.165
WBC count (103/uL) 0.074 0.164
Platelet count (103/uL) 0.046 0.273
PDW (fL) 0.120 0.056
MPV (fL) 0.189 0.006
AST (IU/L) 0.028 0.357
ALT (IU/L) 0.018 0.406
BUN (mg/dL) -0.100 0.096
Creatinine (mg/dL) 0.128 0.047
Uric acid (mg/dL) 0.187 0.007
Cholesterol (mg/dL) 0.016 0.421
ESR (mm/hr) 0.165 0.023
CRP (mg/L) 0.152 0.030
PASI, Psoriasis Area Severity Index; WBC, whole blood cell; PDW, platelet 
distribution width; MPV, mean platelet volume; AST, aspartate amino-
transferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Table 3. The Comparison of Clinical Characteristics of Psoriasis Patients with PASI<10 and PASI≥10 
Characteristics PASI<10 (n=124) PASI≥10 (n=52) p value
Age (yrs)           40±15.63 39.40±14.12 0.406
Gender (n, M/F) 79/45 36/16 0.603
Hemoglobin (g/dL)    14.47±1.45  14.55±1.73 (n=47) 0.388
WBC count (103/uL)        6.7±1.74  7.209±2.17 (n=47) 0.057
Platelet count (103/uL) 245.3±47   254.3±49.19 0.128
PDW (fL)    11.39±1.43 11.68±1.49 0.110
MPV (fL)    9.862±0.75 10.08±0.67 0.038
AST (IU/L) 21.58±8.96 (n=123)   21.31±9.59 (n=45) 0.434
ALT (IU/L)   24.56±17.55 (n=123)     27.42±23.78 (n=45) 0.199
BUN (mg/dL) 13.67±4.07 (n=121) 12.55±3.6 (n=51) 0.045
Creatinine (mg/dL)   0.85±0.19 (n=121)     0.86±0.15 (n=51) 0.353
Uric acid (mg/dL)   5.20±1.36 (n=121)     5.45±1.30 (n=49) 0.145
Cholesterol (mg/dL)   185.1±36.79 (n=116)     185.6±37.29 (n=47) 0.466
ESR (mm/hr)   15.49±15.69 (n=104)     17.47±19.06 (n=43) 0.258
CRP (mg/L)     2.13±7.770 (n=106)     4.134±8.540 (n=47) 0.078
PASI, Psoriasis Area Severity Index; WBC, whole blood cell; PDW, platelet distribution width; MPV, mean platelet volume; AST, aspartate aminotransfer-
ase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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concept, previous studies suggest that platelet activation is 
increased in patients with psoriasis.15,16 Among the wide ar-
ray of methods measuring platelet activation, MPV and 
PDW are most simple parameters to estimate platelet activ-
ity.17 Especially, MPV level has been investigated in diverse 
diseases.17 
In our current study, we also showed that MPV and PDW 
were significantly increased in psoriasis patients compared 
to healthy controls. In addition, MPV showed statistically 
markers. Several indicators of inflammation and immune re-
sponse are known to be elevated in psoriasis, including CRP, 
E-selectin, intracellular adhesion molecule-1, haptoglobin 
and pro-inflammatory cytokines interleukin (IL)-1β, IL-6, 
IL-8, IL-12, IL-18, and tumour necrosis factor-α.11-13 Al-
though there are no clinically relevant biomarkers for psori-
asis, increase of these indicators in peripheral circulation 
definitely reflects the recent trend that psoriasis is deeply as-
sociated with various systemic diseases.14 In line with this 
Fig. 2. Psoriasis patients are divided into mild group (PASI<10) and moder-
ate, severe group (PASI≥10). Values and mean values of MPV are shown. 
PASI, Psoriasis Area Severity Index; MPV, mean platelet volume.
Fig. 3. Psoriasis patients are divided into two groups according to their 
MPV value (MPV<10.4 fL and MPV≥10.4 fL). PASI scores of the patients in 
each group are shown. PASI, Psoriasis Area Severity Index; MPV, mean 
platelet volume.
Table 4. The Comparison of Clinical Characteristics of Psoriasis Patients with MPV<10.4 fL and MPV≥10.4 fL 
Characteristics MPV<10.4 (n=132) MPV≥10.4 (n=44) p value
Age (yrs) 40.11±15.57 38.98±14 0.335
Gender (n, M/F) 84/48 30/14 0.716
PASI   8.35±7.90   9.18±6.32 0.265
Hemoglobin (g/dL) 14.34±1.56      15±1.20 0.006
WBC count (103/uL)   6.81±1.84   6.86±1.91 0.446
Platelet count (103/uL) 254.60±48.78 228.20±38.35 0.001
PDW (fL) 10.89±0.92 13.25±1.31 <0.001
AST (IU/L) 21.16±7.70 (n=129)   22.43±12.07 (n=44) 0.209
ALT (IU/L)   24.71±17.12 (n=129)   27.07±24.37 (n=44) 0.242
BUN (mg/dL) 13.58±4.08 (n=130) 12.59±3.47 (n=42) 0.081
Creatinine (mg/dL)   0.85±0.19 (n=130)   0.88±0.15 (n=42) 0.166
Uric acid (mg/dL)   5.20±1.36 (n=127)   5.48±1.29 (n=43) 0.126
Cholesterol (mg/dL)   185.3±37.05 (n=120)      185±36.60 (n=43) 0.479
ESR (mm/hr)   15.14±15.02 (n=110)   18.84±20.92 (n=37) 0.122
CRP (mg/L)   3.09±9.11 (n=116)   1.68±2.50 (n=37) 0.177
PASI, Psoriasis Area Severity Index; WBC, whole blood cell; PDW, platelet distribution width; MPV, mean platelet volume; AST, aspartate aminotransfer-
ase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
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chemokines.18 In particular, among many chemokines and 
cytokines of platelets, CXCL8 and IL-1β are of interest to 
psoriasis researchers.19,20 CXCL8 is strongly associated with 
pathogenesis of psoriasis.21 Its production by peripheral 
blood mononuclear cells (PBMCs) was significantly in-
creased and CXCL8 plasma levels were also elevated in 
psoriasis patients.22,23 IL-1β is one of the vital cytokines in-
volved in the activation of psoriasis, and it’s production by 
PBMCs shows positive correlation with PASI in psoriasis 
patients.24,25 Therefore, it will be interesting to investigate 
the possible contribution of CXCL8 and IL-1β from plate-
lets to psoriasis development. In addition to proinflammatory 
mediators, platelets are equipped with adhesive molecules 
and immune receptors on their surface, which connects plate-
lets to the immune system.1 These surface receptors include 
P-selectin, integreins, CD40, Toll-like receptors and chemo-
kine receptors.1,26-28 
With both surface receptors and stored mediators, plate-
lets are able to respond to the variety of stimuli and release 
several mediators to activate other cells and inflammatory 
responses. 
In psoriasis, alterations in platelets function have been also 
demonstrated by various methods other than MPV assess-
ment. Such methods include measurements of platelet ag-
gregation, arachidonic acid transforming capability and as-
sessing plasma levels of P-selectin, platelet factor 4 and ß-
thromoboglobulin.2,29 The mounting evidences from these 
studies definitely confirm that platelets are activated and in-
voloved in pathogenesis of psoriasis. However, the precise 
relationship between platelet activation and pathogenesis of 
significant correlation with PASI in psoriasis patients, but 
PDW did not show significant correlation. Among psoriasis 
patients, moderate to severe patients revealed significantly 
increased MPV level compared to mild patients. In addi-
tion, MPV decreased significantly after the psoriasis treat-
ments and the variations of PASI and MPV showed signifi-
cant correlation. 
As described at the beginning, there are two previous re-
ports regarding MPV in psoriasis patients, however, with 
conflicting results.8,9 Saleh, et al.9 recently revealed no dif-
ference of MPV between psoriasis patients and controls, 
whereas the study of Canpolat, et al.8 was in line with our 
result, which showed significantly increased MPV level in 
psoriasis patients compared to controls. Twenty-five and 
106 psoriasis patients were analyzed in these studies, respec-
tively. Since former study included only 25 patients, which 
showed no difference of MPV between psoriasis patients 
and controls, and studies done by Canpolat, et al.8 and our 
group included much more patients, we think that MPV lev-
el could be actually increased in psoriasis patients compared 
to controls. Moreover, in both studies, MPV value showed 
positive correlation with PASI. Therefore, these findings un-
derpin significant correlation between MPV and psoriasis, 
which implies that activity of platelet is closely related to 
the pathogenesis of psoriasis. 
Platelets have important role in immune responses and 
inflammatory reactions, not to mention their key functions 
in hemostasis and thrombosis.1 Various proinflammatory 
mediators are stored in platelets, such as adenosine diphos-
phate, adenosine triphosphate, serotonin, cytokines, and 
Fig. 4. (A) The MPV levels of psoriasis individuals were evaluated before and after the treatments. (B) The correlation between the variations of PASI 
(ΔPASI) and the variation of MPV (ΔMPV) was analyzed. PASI, Psoriasis Area Severity Index; MPV, mean platelet volume.
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pha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients 
with active psoriasis and correlation with disease severity. Media-
tors Inflamm 2005;2005:273-9.
14. Boehncke WH. Perspective: Don’t be superficial. Nature 2012; 
492:S55.
15. Berrettini M, Parise P, Constantini V, Grasselli S, Nenci GG. 
Platelet activation in psoriasis. Thromb Haemost 1985;53:195-7.
16. Hayashi S, Shimizu I, Miyauchi H, Watanabe S. Increased platelet 
aggregation in psoriasis. Acta Derm Venereol 1985;65:258-62.
17. Leader A, Pereg D, Lishner M. Are platelet volume indices of clini-
cal use? A multidisciplinary review. Ann Med 2012;44:805-16.
18. Offermanns S. Activation of platelet function through G protein-
coupled receptors. Circ Res 2006;99:1293-304.
19. Gear AR, Camerini D. Platelet chemokines and chemokine recep-
tors: linking hemostasis, inflammation, and host defense. Micro-
circulation 2003;10:335-50.
20. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello 
CA. Activated platelets induce endothelial secretion of interleu-
kin-8 in vitro via an interleukin-1-mediated event. Blood 1993;81: 
2492-5.
21. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michal-
ak-Stoma A, Nockowski P, et al. Cytokines and anticytokines in 
psoriasis. Clin Chim Acta 2008;394:7-21.
22. Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K. 
Increased spontaneous production of IL-8 in peripheral blood 
monocytes from the psoriatic patient: relation to focal infection 
and response to treatments. J Dermatol Sci 1995;10:8-15.
23. Pietrzak A, Kozioł-Montewka M, Lecewicz-Toruń B, Krasowska 
D. Is there any correlation between the total number of neutrophils 
in plasma and concentration of interleukin-8 in psoriatic patients? 
Med Sci Monit 2000;6:867-70.
24. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleu-
kin-1: a key inflammatory mediator in psoriasis? Cytokine 2006; 
33:72-8.
25. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role 
of increased production of monocytes TNF-alpha, IL-1beta and 
IL-6 in psoriasis: relation to focal infection, disease activity and 
responses to treatments. J Dermatol Sci 1997;14:145-53.
26. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a 
granule membrane protein of platelets and endothelium: sequence 
similarity to proteins involved in cell adhesion and inflammation. 
Cell 1989;56:1033-44.
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and signaling in platelets. Blood 2004;104:1606-15. 
28. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi 
C. Cutting edge: T cells trigger CD40-dependent platelet activa-
tion and granular RANTES release: a novel pathway for immune 
response amplification. J Immunol 2004;172:2011-5.
29. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto 
S. Elevated platelet activation in patients with atopic dermatitis 
and psoriasis: increased plasma levels of beta-thromboglobulin 
and platelet factor 4. Allergol Int 2008;57:391-6.
psoriasis has not been clearly proved. Activated platelets 
could participate in the development of psoriasis. On the 
other hand, platelets could just be bystanders and systemic 
inflammation of psoriasis led to their activation. Therefore, it 
would be interesting to find out whether activated platelets 
are the cause or effect of systemic inflammation in psoriasis. 
In conclusion, MPV levels are increased in patients with 
psoriasis, especially in severe patients and the change of 
MPV in psoriasis individual was closely related to the clini-
cal severity. However, precise clinical relevance of MPV 
and the role of activated platelets in psoriasis need to be 
further investigated by comprehensive propective trials and 
translational research, respectively. 
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